These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12077579)

  • 1. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS.
    Eliaszewicz M; Flahault A; Roujeau JC; Fillet AM; Challine D; Mansouri S; Wolkenstein P; Aractingi S; Penso-Assathiany D; Maslo C; Bourgault-Villada I; Chosidow O; Caumes E;
    J Am Acad Dermatol; 2002 Jul; 47(1):40-6. PubMed ID: 12077579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.
    Wolkenstein P; Loriot MA; Aractingi S; Cabelguenne A; Beaune P; Chosidow O
    Pharmacogenetics; 2000 Dec; 10(9):821-8. PubMed ID: 11191886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cerebral toxoplasmosis in HIV infected patients intolerant of cotrimoxazole].
    Rabaud C; May T; Beuscart C; Reynes J; Leport C; Canton P
    Ann Med Interne (Paris); 1998 Mar; 149(2):62-6. PubMed ID: 11490526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis].
    Caumes E
    Rev Mal Respir; 1996; 13(2):101-6. PubMed ID: 8711227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumocystosis in infants and children with HIV: current concepts.
    Dollfus C
    Pediatr Pulmonol Suppl; 1997; 16():194-6. PubMed ID: 9443271
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia.
    Caumes E; Roudier C; Rogeaux O; Bricaire F; Gentilini M
    Clin Infect Dis; 1994 Mar; 18(3):319-23. PubMed ID: 8011811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reactions to sulphonamides in patients with HIV infection.
    Federico G; Del Forno A; Del Borgo C; Ricci F; Tumbarello M; Fantoni M
    J Chemother; 1995 Nov; 7 Suppl 4():190-2. PubMed ID: 8904152
    [No Abstract]   [Full Text] [Related]  

  • 9. [Intolerance to sulfonamides in HIV infected subjects. Toxic and allergic origin].
    Mathelier-Fusade P; Leynadier F
    Presse Med; 1993 Oct; 22(29):1363-5. PubMed ID: 8248069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-induced toxicoderma. Diagnosis].
    Wolkenstein P; Chosidow O
    Rev Prat; 1997 Feb; 47(3):327-33. PubMed ID: 9122608
    [No Abstract]   [Full Text] [Related]  

  • 11. No association between HLA-B and cutaneous reactions to sulphonamides in human immunodeficiency virus-infected patients.
    Vitezica ZG; Wolkenstein P; Lonjou C; Eliaszewicz M; Sicard X; Roujeau JC; Hovnanian A
    Br J Dermatol; 2008 Aug; 159(2):501-3. PubMed ID: 18547316
    [No Abstract]   [Full Text] [Related]  

  • 12. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
    Boonyagars L; Hirunwiwatkul P; Hurst CP
    Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of AIDS-defining diseases: temporal trends in Italy prior to the use of highly active anti-retroviral therapies, 1982-1996.
    Pezzotti P; Serraino D; Rezza G; Dal Maso L; Vaccher E; Lepri AC; Franceschi S
    Int J Epidemiol; 1999 Oct; 28(5):975-81. PubMed ID: 10597999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug eruptions in HIV infection].
    Roujeau JC
    Presse Med; 1994 Jan; 23(3):111-2. PubMed ID: 8177841
    [No Abstract]   [Full Text] [Related]  

  • 15. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003.
    Teshale EH; Hanson DL; Wolfe MI; Brooks JT; Kaplan JE; Bort Z; Sullivan PS;
    Clin Infect Dis; 2007 Mar; 44(6):879-83. PubMed ID: 17304464
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous adverse reactions to sulfonamide antibiotics.
    Chantachaeng W; Chularojanamontri L; Kulthanan K; Jongjarearnprasert K; Dhana N
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):284-9. PubMed ID: 22053600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study.
    Heald A; Flepp M; Chave JP; Malinverni R; Rüttimann S; Gabriel V; Renold C; Sugar A; Hirschel B
    Ann Intern Med; 1991 Nov; 115(10):760-3. PubMed ID: 1929023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.
    Su YS; Lu JJ; Perng CL; Chang FY
    J Microbiol Immunol Infect; 2008 Dec; 41(6):478-82. PubMed ID: 19255691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of patients infected by the human immunodeficiency virus (HIV). Report of an expert group].
    Delfraissy JF;
    Rev Pneumol Clin; 2002 Dec; 58(6 Pt 1):312-40. PubMed ID: 12545131
    [No Abstract]   [Full Text] [Related]  

  • 20. [Round Table: Urticaria in relation to infections].
    Bilbao A; García JM; Pocheville I; Gutiérrez C; Corral JM; Samper A; Rubio G; Benito J; Villas P; Fernández D; Pijoán JI
    Allergol Immunopathol (Madr); 1999; 27(2):73-85. PubMed ID: 10354011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.